Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan

a technology of carrageenan and rhinovirus, applied in the field of immunology and antiviral agents, can solve problems such as the development of vaccines, and achieve the effects of preventing or reducing the risk of infection, and being easy to incorporate into the tissue material

Inactive Publication Date: 2008-06-05
MARINOMED BIOTECHNOLOGIE GMBH
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0017]In other embodiments, the present invention provides hygiene or sanitation articles comprising the polymer (carrageenan selected from lambda-, iota- or kappa-carrageenan or mixtures thereof), as homo- or heteropolymers, preferably tissues or handkerchiefs. In particular, the hygiene or sanitation article is a facial hygiene or sanitation article, preferably for the oral and/or nasal area, especially preferred being for topical or mucosal use, most prefer...

Problems solved by technology

Because of the large number of serotypes, development of a vaccine is p...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
  • Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan
  • Methods and Compositions for the Treatment of Rhinovirus Infections with Carrageenan

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Different Types of Carageenans Against Human Rhinovirus Type 2 and Type 14

[0030]Subconfluent HeLa cells were incubated with a virus suspension that was preincubated for 5 min with 125 μg / ml of the indicated polymers. 48 hours later the viability of the cells was determined with TOX2 XTT assay (Sigma). (FIG. 1). Error bars indicate the standard deviation between six independent wells. The most effective polymer was iota-carrageenan that was effective against both types of rhinovirus while, lambda-carrageenan and kappa-carrageenan showed effectivity for HRV-2 but not for HRV-14.

example 2

[0031]The polymers indicated in Table 1 were tested in a HRV-2 and HRV-14 induced cell death inhibition assay (XTT-assay) at a concentration of 100 μg / ml: iota Carageenan showed protection against both types of Rhinovirus. Kappa Carageenan and lambda carrageenan, were active against HRV-2 but not against HRV-14. The polymers Chitosan, Carboxymethylcellulose and Carboxymethylchitosan did not show an inhibitory effect.

example 3

[0032]Iota-Carageenan is effective against HRV-2 and HRV-14 in a treatment and a prophylaxis viral replication model. A significant reduction of peak viral titer was observed at concentrations equal and higher than 6.25 μg / ml. However, iota carageenan was most effective in the prophylaxis model against HRV-2 in which a reduction of more than 99.9% in the peak viral titer was observed.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to view more

Abstract

The present invention provides the use of carrageenan or mixtures thereof for the manufacture of an antiviral pharmaceutical composition for the treatment of rhinovirus infections.

Description

BACKGROUND OF THE INVENTION[0001]1. Field of the Invention[0002]The present invention relates to the field of immunology and antiviral agents.[0003]2. Description of Related Art[0004]Picornaviruses represent a very large virus family of small ribonucleic acid-containing viruses responsible for many serious human and animal diseases. Picornaviruses include four major groups: enteroviruses, rhinoviruses, cardioviruses and apthoviruses.[0005]The human rhinoviruses consist of at least 100 serotypes and are the primary causative agents of the common cold. Because of the large number of serotypes, development of a vaccine is problematic; antiviral agents may therefore be the best approach to treatment. Rhinoviruses are composed of a surrounding capsid, which contains four viral proteins VP1, VP2, VP3 and VP4. Proteins VP1, VP2 and VP3 are organized into 60 repeating protameric icosahedral units. These are thought to be the cause of antigen diversity associated with these viruses.[0006]Rhi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/02A61P31/16A61P11/06
CPCA61K31/731A61P11/06A61P31/16
Inventor GRASSAUER, ANDREASPRIESCHL-GRASSAUER, EVAMEIER, CHRISTIANEPRETSCH, ALEXANDER
Owner MARINOMED BIOTECHNOLOGIE GMBH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap